FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours nor resnance.	0.5									

					01 3	CUIC	30(11)	JI LITE	invesiment	CUII	ipariy Aci	01 1940							
Name and Address of Reporting Person*     Knowles Julius				2. Issuer Name <b>and</b> Ticker or Trading Symbol Keros Therapeutics, Inc. [ KROS ]								(Che	eck all appli	onship of Reporting Person(s) to Issuer Il applicable)  Director 10% Owner					
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023										(give title		Other (s below)		
C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302				4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Application)     X Form filed by One Reporting Person							
(Street) LEXINGTON MA 02421														Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									ed to					
		Tab	le I - Non-	Deriva	ative	Sec	curities	s Ac	quired, C	Disp	osed o	of, or Be	enefi	iciall	y Owned	t			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						r)   E	2A. Deemed Execution Date, if any (Month/Day/Yea		r, Transaction Disp Code (Instr. 5)			ecurities Acquired (A posed Of (D) (Instr. 3,			Benefici	es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount (A) or (D)		or P	rice	Transact (Instr. 3	ction(s)			(Instr. 4)
		T	able II - De (e						uired, Dis s, options						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title at Amount Securitie Underlyi Derivativ (Instr. 3 a	of s ng e Secu	urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ve es ally g d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				С	ode	v	(A)	(D)	Date Exercisable		opiration	Title	Amo or Nun of Sha						
Stock Option	\$48.79	06/06/2023			A		10,000		(1)	06	5/05/2033	Common	10,	000	\$0.00	10,000	)	D	

## **Explanation of Responses:**

1. The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

## Remarks:

/s/ Keith Regnante, Attorneyin-Fact
\*\* Signature of Reporting Person

06/08/2023

directly or indirectly

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.